Clinical efficacy and cost-effectiveness analysis in patients with hormone replacement for frozen-thawed embryo transfer under different luteal support scheme
10.3760/cma.j.cn101441-20200526-00313
- VernacularTitle:不同黄体支持方案在激素替代周期冻胚移植中的临床疗效及成本分析
- Author:
Ye ZHENG
1
;
Yanbo DU
1
;
Huidan WANG
1
;
Yan SHENG
1
;
Xiufang LI
1
Author Information
1. 山东大学附属生殖医院，济南250021
- Publication Type:Journal Article
- Keywords:
Luteal support;
Cost-effectiveness analysis;
Frozen-thawed embryo transfer;
Hormone replacement;
Pregnancy outcomes
- From:
Chinese Journal of Reproduction and Contraception
2022;42(1):17-23
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the differences in pregnancy outcomes of patients and cost variance with hormone replacement therapy for frozen-thawed embryo transfer (HRT-FET) under different luteal support scheme.Methods:A retrospective cohort study was performed. A total of 1009 cycles of HRT-FET from October 2017 to April 2019 were collected and the patients were recruited from Reproductive Hospital Affiliated to Shandong University. According to different luteal support protocol, patients in group A ( n=504) were treated with oral progesterone capsule while patients in group B ( n=505) were treated with progesterone vaginal sustained release gel and dydrogesterone. The pregnancy outcomes, pregnancy complications and cost-effectiveness ratio were compared between the two groups. Results:There were no significant differences in embryo implantation rate, clinical pregnancy rate, multiple pregnancy rate, ectopic pregnancy rate, early and late abortion rate, premature birth rate, live birth rate, incidence of pregnancy complications and birth defect rate between the two groups (all P>0.05). But the incidence of vaginal bleeding in group B was significantly higher than that in group A [6.0% (30/504) vs. 10.3% (52/505), P=0.015], cost-effectiveness ratio (C/E) in group A was better than that in group B (17.76 vs. 77.30). Conclusion:For patients undergoing HRT-FET cycles, oral progesterone capsule can reduce vaginal bleeding and medical cost, while achieving a pregnancy outcome similar to that of progesterone vaginal sustained release gel and dydrogesterone, so it can be used as a luteal support scheme in clinic.
